Fresenius Medical Care
Country
Germany
Sector
Healthcare-Services
Offices
-
Employees
-
Brand value
$3,894m
Brand rating
AA-
Enterprise value
$26,221m
Value / market cap
14.9%
This brand has received no votes.
Market cap
* For banks, enterprise value is substituted with market cap. Source: Bloomberg Finance L.P.
Performance of the brand
Fresenius Medical Care AG provides patients with kidney disease with innovative technologies and treatment concepts by covering the entire dialysis value chain. Fresenius Medical Care counts over 73,000 employees worldwide, working on more than 40 production sites and 2,757 clinics (2010) to provide products and services to over 200,000 customers around the globe. This makes Fresenius the world’s largest provider of dialysis products and services to patients suffering from chronic kidney failure. Within 2010, net revenues totalled $12,053 million, a 7% increase over the 2009 results. At this, 67% of net revenues were generated by North America, followed by 21% for Europe/Middle East/Africa, 7% for Asia-Pacific, and 5% for Latin America. The dialysis products segment, covering dialysers, dialysis machines, bloodlines etc. represents 55% of all revenues, while 45% fall under various dialysis services offered in clinical centres.
When looking at Fresenius Medical Care’s brand valuation results, a similar trend can be observed. Listed on rank 262 within The BrandFinance® Global 500 2011, Fresenius increased its brand value from $3,027 million in 2010 to $3,949 million in 2011 (+30.5%). At the same time, enterprise value increased by 9.6% to $24,162 million in 2011. If Fresenius Medical Care AG continues its rise within the dialysis segment, there will be no doubt about a positive outcome within the 2012 brand valuation results.
League tables
Fresenius Medical Care appears in the following brand league tables:
Rank 269 in the
Global 500 2012.
Rank 21 in the
Germany 30 2012.
Rank 262 in the
Global 500 2011.
Rank 262 in the
Global 500 2011.
Rank 20 in the
Germany 30 2011.
Rank 294 in the
Global 500 2010.
2012 brand performance*
Brand value
$3,894m
Brand rating
AA-
Enterprise value
$26,221m
Value / ent. value
14.9%
* Figures taken on 31st December 2011.
2011 brand performance*
Brand value
$3,949m
Brand rating
AA
Enterprise value
$24,162m
Value / ent. value
16.3%
* Figures taken on 31st December 2010.
2010 brand performance*
Brand value
$3,027m
Brand rating
AA
Enterprise value
$21,830m
Value / ent. value
13.9%
* Figures taken on 31st December 2009.
Mission statement
"Creating a future worth living. For people. Worldwide. Every day."
Company history
Although Fresenius Medical Care AG was only founded in 1996, its history dates back to the 18th century. In 1462, the first Hirsch-pharmacy was established in Frankfurt am Main, Germany, which, in the 18th century, came under the ownership of the Fresenius family. Dr. Eduard Fresenius himself started with the production of pharmaceuticals in 1912, followed by the establishment of a separate production plant in Bad Homburg. In the 1970s, Fresenius started to expand its business into the dialysis segment, primarily focusing on the production of dialysers. In 1996, finally, Fresenius Medical Care had its IPO at the Frankfurt and New York Stock Exchange and was officially founded. During the early 2000s, the company soon became one of the market leaders within the dialysis business, serving more than 120,000 patients all over the globe. In March 2006, Fresenius acquired the Renal Care Group, Inc., developing and operating dialysis centres across the United States. This acquisition further fostered Fresenius’ position as market leader, resulting in the production of 500 million dialysers in 2007. Until today, Fresenius Medical Care AG has been providing over 30 million dialysis treatment to more than 200,000 patients worldwide.
Key people
Dr. Ben J. Lipps, CEO
Dr. Ben J. Lipps serves as Chief Executive Officer of Fresenius Medical Care since 1999. Prior to that, he was CEO of Fresenius Medical Care North America from 1996 to 1999 and of Fresenius U.S. from 1985 to 1996. After earning his master’s degree and doctorate in Chemical Engineering at the Massachusetts Institute of Technology, he led the research team at Dow Chemical that developed the first commercial hollow-fiber artificial kidney at the end of the 1960s.
Michael Brosnan, CFO
Michael Brosnan serves as Chief Financial Officer since January 2010. Previously, he served as Chief Financial Officer of Fresenius Medical Care North America for seven years. He joined the Company in 1998 as Vice President of Finance and Administration for Spectra Renal Management, the Company’s laboratory services organization. Subsequently, he assumed several executive functions at Fresenius Medical Care North America. Prior to joining the Company, he held senior financial positions at Polaroid Corporation and was an audit partner at KPMG.
